cadisegliatin
Small molecule
Evidence outlook · registrational
Type 1 Diabetes: registrational readout pending
Its supporting mid-stage studies have completed. ClinicalTrials.gov estimates the registrational readout at 2027-04; company guidance (vTv Therapeutics, stated 2026-11-05): topline data expected mid-2027.
Company guidance: topline data expected mid-2027 (NCT06334133; vTv Therapeutics, 5 Nov 2026). “A total of 166 patients were randomized in the study and the Company expects to report topline results from the CATT1 study in mid-2027.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
CATT1 NCT06334133 · Type 1 Diabetes Registry: NCT06334133 | 3 | Change in incidence of Level 2 or Level 3 hypoglycemia (26 weeks) 2027-04 | In progress: results expected 1 Apr 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Competitive landscape
Other Glucokinase drugs
Dorzagliatin, PB-201, Globalagliatin Hydrochloride, HMS1005. Compare all 5 Glucokinase drugs
4 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Type 1 Diabetes: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Cadisegliatin: this drug | Phase 3 | Small molecule | Glucokinase | not yet graded | No reviewed efficacy summary in this indication | |
| Afrezza | Approved | Peptide | Insulin | Partial signal | NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed NCT01445951: Change in HbA1c from baseline to week 24 (LS mean): Technosphere Insulin (Gen2 inhaler) plus basal insulin -0.21% vs insulin aspart plus basal insulin -0.40%; difference 0.19% (95% CI 0.02 to 0.36), inside the pre-specified non-inferiority margin of 0.4% (CT.gov posted analysis). | |
| Insulin Aspart (NovoLog) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Aspart (Fiasp) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Degludec (Tresiba) | Approved | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Detemir (Levemir) | ApprovedUS marketing discontinued | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Glargine (Lantus) | Approved | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Glargine (Basaglar) | Approved | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Glargine (Toujeo) | Approved | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Glulisine (Apidra) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Human | Approved | — | Insulin | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Lispro (Humalog) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Lispro (Lyumjev) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin NPH (Humulin N) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Pramlintide (Symlin) | ApprovedUS marketing discontinued | Peptide | Amylin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Dorzagliatin (Huatangning) | Phase 3(overall) | Small molecule | Glucokinase | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| PB-201 | Phase 3(overall) | Small molecule | Glucokinase | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Sotagliflozin (Inpefa) | Phase 3 | Small molecule | SGLT1/2 (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Zimislecel | Phase 3 | Cell therapy | Pancreatic islet cells (VX-880 is a stem cell-derived therapy, not a small molecule drug), Pancreatic islet cell replacement | not yet graded | No reviewed efficacy summary in this indication | |
| Globalagliatin Hydrochloride | Phase 2(overall) | Small molecule | Glucokinase | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Icovamenib | Phase 2 | Small molecule | Menin | not yet graded | No reviewed efficacy summary in this indication | |
| HMS1005 | Phase 1(overall) | Small molecule | Glucokinase | Partial signal(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow cadisegliatin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
April 2027 (1)
Company guidance: topline data expected mid-2027 (vTv Therapeutics, 5 Nov 2026). “A total of 166 patients were randomized in the study and the Company expects to report topline results from the CATT1 study in mid-2027.” Source ↗